BeOne Medicines Launches After Move to Switzerland
BeOne Medicines Ltd., a global oncology company formerly known as BeiGene, Ltd., today announced its new name and redomiciliation to Switzerland are officially in effect,...
Tag : clinical development
Azafaros Raises €132M in Series B for Phase 3 Lysosomal Therapies
Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of...
Sirius Therapeutics Raises $50M for siRNA Cardiometabolic Therapy
Sirius Therapeutics today announced that it has successfully completed nearly $50 million Series B2 financing to advance clinical development of the Company’s novel siRNA therapeutics...
AN2 Therapeutics Shares Phase 3 EBO-301 Data and Future Milestones
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced...
Ray Therapeutics Gets $8M CIRM Grant for RP Gene Therapy
Funding will support ongoing clinical development of optogenetic therapy to restore vision Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for vision restoration, today...
Onward Therapeutics Announces IMPD Approval for OT-C001 Trial
Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD)...
Vantage Biosciences Begins Phase 2 Trial of Oral VX-01 for NPDR
Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in...
Advanced Therapies Europe 2025 Debuts Curated 500-Attendee Format
Advanced Therapies Europe arrives in Barcelona for the first time, taking place from 2-4 September 2025 at the Hotel Arts, Ritz-Carlton. With a bold new focus, this year’s edition...
ABL Bio Licenses Grabody-B Platform to GSK for Brain Drugs
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across...
BeiGene Ends Ociperlimab Clinical Program Following Futility Analysis
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the...
Infinitopes Adds Two Biotech Leaders to Board for Immunotherapies
Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to...
Xeltis Adds Leading Experts to Medical Advisory Board
Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement Xeltis, a leading developer of transformative implants that enable the natural...